AMD

See the results from our recent poll!

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

Kicking off AMD Awareness Month, give us your thoughts!

Benefits include eliminating eyeglass problems and boosting patient confidence.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.

A multicenter US study revealed that the long-term use of metformin to treat diabetes and lifestyle changes in patients with diabetes were not associated with the risk of age-related macular degeneration (AMD).

As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!

Brad Sutton, OD, FAAO, FORS, discusses key takeaways from his discussion, "Genetic testing in AMD: critical, useful, or inappropriate," which he presented during the 2022 American Academy of Optometry meeting.

Anthony DeWilde, OD, FAAO, shares highlights from his AAOpt presentation, "Anti-VEGF and the eye: Past, present and future."

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

In honor of World Sight Day, optometrists and ophthalmologists reflect on what today means to them.

Treatment suspension has negative impact on visual function.

AREDS2 formula doesn’t contain beta carotene, reducing the risk of lung cancer.

With the launch of dark adaptation, Heru is now the only platform on the AMD market to include contrast sensitivity and dark adaptation exams.

Ashley Tucker, OD, FAAO, FSLS, Dipl ABO, shares highlights from her discussion titled, "Myopia management: past, present, and future," presented during this year's 115th annual SCOPA meeting.

Leo P. Semes, OD, FAAO, highlights his presentation on "Artificial intelligence and telemedicine," presented during the 115th annual SCOPA meeting.

Leo P. Semes, OD, FAAO, discusses his presentation on, "A new look at AMD," during the South Carolina Optometric Physicians Association's annual meeting.

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

Korean investigators have found intermittent fasting may actually lead to a lower risk of developing AMD in the elderly population.

Presented during the 2022 ASRS meeting, results find that over 60% of participants could be treated every 4 months at 2 years—an increase from 45% at year 1.

A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.

Trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.

Elena Biffi, OD, MSc, FAAO, dives into AMD, a multifactorial disease that requires a multimodal diagnostic imaging approach.

Embracing this new model of care can allow optometric practices to flourish—and may enable earlier detection of conversion from intermediate dry to wet AMD.

Early diagnosis and intervention are crucial when managing this patient base.

A decision by the FDA is expected in August 2022.

The company, formerly known as Clover Therapeutics, intends to use the funding to advance two lead drug candidates that target molecularly-defined AMD patient subtypes.

The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.